HAG
INDP icon

HighPoint Advisor Group’s Indaptus Therapeutics INDP Stock Holding History

HighPoint Advisor Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-89
Closed -$59K – 528
2020
Q4 		$59K Buy
+89
New +$38.8K 0.01% 468

Other funds holding INDP

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

HighPoint Advisor Group's INDP Position: Q1 2021 in Review

HighPoint Advisor Group sold out of Indaptus Therapeutics (INDP) in Q1 2021, closing a stake of 89 shares — an estimated $59K sold.

HighPoint Advisor Group first reported a position in INDP in Q4 2020 and held it in 1 quarter. The position peaked at $59K in Q4 2020. 17 funds tracked by Wall St. Rank hold INDP as of Q1 2021.

  • HighPoint Advisor Group reported no remaining Indaptus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • HighPoint Advisor Group sold 89 Indaptus Therapeutics shares in Q1 2021, an estimated $59K.
  • HighPoint Advisor Group first reported a position in Indaptus Therapeutics in Q4 2020 and held it in 1 quarter.
  • HighPoint Advisor Group's Indaptus Therapeutics position peaked at $59K in Q4 2020.
  • 17 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2021.

Based on HighPoint Advisor Group's 13F filing for Q1 2021, filed 12 Apr 2021.